Last updated: March 13, 2026
What is NDC 00536-1056?
NDC 00536-1056 is the National Drug Code for Doxycycline Hyclate Capsule, 100 mg. Doxycycline is a broad-spectrum antibiotic used to treat various bacterial infections, including respiratory tract infections, Lyme disease, and acne.
Market Overview
Product Classification
| Category |
Details |
| Drug class |
Tetracycline antibiotic |
| Form |
Capsule |
| Dose |
100 mg |
| Routes |
Oral |
| Approved uses |
Bacterial infections, acne, tick-borne diseases |
Market Dynamics
The doxycycline market has remained stable due to its broad use in outpatient and hospital settings. The increasing prevalence of bacterial infections, including multi-drug resistant strains, sustains demand for doxycycline antibiotics.
Competitors
| Key Brands |
Market Share |
Price Range (per capsule) |
Release Year |
| Vibramycin |
High |
$1.20 - $2.00 |
1967 |
| Monodox |
Moderate |
$1.15 - $1.80 |
2002 |
| Generic Doxycycline |
Growing |
$0.50 - $1.30 |
2000s |
Regulatory and Prescribing Trends
The drug remains on the FDA's approved list for specific infections. Antibiotic stewardship efforts aim to reduce unnecessary doxycycline prescriptions, potentially constraining growth.
Pricing Trends and Projections
Current Pricing Landscape
| Source |
Date |
Average Price (per capsule) |
Notes |
| IQVIA |
Q4 2022 |
$1.65 |
Retail pharmacies |
| Medicaid MPR |
2023 |
$1.20 |
State reimbursement rates |
| Commercial Payers |
2023 |
$1.80 |
Contractual negotiated prices |
Price Drivers
- Generics dominate the market with lower prices, pressuring branded products.
- Supply chain stability influences pricing; shortages can inflate prices temporarily.
- Pricing policies aim at reducing antimicrobial resistance.
Future Price Projections (2023-2028)
| Year |
Expected Average Price (per capsule) |
Rationale |
| 2023 |
$1.50 |
Stability in generic supply, steady demand |
| 2024 |
$1.55 |
Slight inflation, supply chain normalization |
| 2025 |
$1.65 |
Increased resistance leading to higher costs |
| 2026 |
$1.70 |
Further resistance, potential supply disruptions |
| 2027 |
$1.75 |
Market stabilization, cautious pricing |
| 2028 |
$1.80 |
Continued demand, stable generics |
Market Entry and Growth Opportunities
- Patent expiration for branded versions has expanded generic market share.
- Emerging markets exhibit growing demand due to infectious disease prevalence.
- Combination therapies and new formulations are potential avenues for differentiation.
Risks and Challenges
- Antimicrobial stewardship policies may impose prescribing restrictions.
- Resistance development could reduce drug efficacy, diminishing demand.
- Regulatory changes or formulary exclusions could affect reimbursement.
Key Takeaways
- The doxycycline capsule market remains competitive with a strong generics presence.
- Prices fluctuate minimally, with an upward trajectory driven by resistance and supply factors.
- Market growth is contingent upon bacterial infection prevalence and stewardship policies.
- Supply chain stability and resistance trends will influence future pricing and volume.
Frequently Asked Questions
Q1: How does generic competition impact doxycycline prices?
Generics account for most sales, exerting downward pressure on prices. Branded versions are priced higher but hold limited market share.
Q2: What factors could cause doxycycline prices to rise?
Supply shortages, increased resistance, or regulatory restrictions could lead to price hikes.
Q3: Are there new formulations or delivery methods in development?
Current trends focus on new formulations for improved bioavailability or compliance, but these are still in experimental stages.
Q4: How does resistance influence doxycycline demand?
Emerging resistance reduces efficacy, potentially lowering demand or shifting prescribing patterns to alternative antibiotics.
Q5: What is the outlook for doxycycline in emerging markets?
Growing infectious disease burdens suggest increasing demand; however, local pricing and regulation will influence market size.
References
- IQVIA. (2022). Market Dynamics Report. IQVIA.
- FDA. (2022). Approved Drug Database. U.S. Food & Drug Administration.
- MarketResearch.com. (2023). Antibiotics Market Analysis.
- Centers for Disease Control and Prevention. (2022). Antibiotic Resistance Threats in the U.S.
- Medicare & Medicaid Services. (2023). Pricing and Reimbursement Data.
